Remove Diabetes Remove Kidney Disease Remove Risk Factors
article thumbnail

SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.

article thumbnail

Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes

Medical Xpress - Cardiology

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

article thumbnail

America’s CKM Syndrome Problem

CardiacWire

Officially published by the AHA six months ago, CKM syndrome defines the connections and risks associated with obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. White) to assess their CKM stages, finding the following breakdown: Stage 0 (no risk factors) – 10.6%

article thumbnail

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes

Cardiovascular Diabetology

Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.

article thumbnail

Microvascular disease, modifiable risk factor profiles and incident arrhythmias in type 2 diabetes

Heart BMJ

Background To assess the roles of diabetic microvascular disease and modifiable risk factors and their combination in the development of arrhythmias. Methods We included participants with type 2 diabetes (T2D) who were free of arrhythmias during recruitment in the UK Biobank study.

article thumbnail

Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney Disease

Journal of the American Heart Association

BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidney disease. Longitudinal associations with cardiovascular mortality and kidney outcomes (eGFR <60 or <45 mL/min per 1.73 1.54]; PGEM HR, 1.36 [95% CI, 1.10–1.67]).

article thumbnail

Resting Heart Rate Independent of Cardiovascular Disease Risk Factors Is Associated With End?Stage Renal Disease: A Cohort Study Based on 476?347 Adults

Journal of the American Heart Association

Participants with an RHR of ≥80 bpm had a higher stage of chronic kidney disease, lower estimated glomerular filtration rate, and more proteinuria than those with an RHR of 60 to 69 bpm. 1.90]) higher risk of ESRD, respectively. The risk of ESRD remained significantly elevated (HR, 1.32 [95% CI, 1.10–1.58]